Date: 2012-07-09
Type of information: Licensing agreement
Compound: Versamune™ nanotechnology platform
Company: Merck KGaA, Merck Serono (Germany) PDS Biotechnology (USA)
Therapeutic area: Cancer - Oncology
Type agreement: licensing
Action mechanism:
Disease:
Details:
- PDS Biotechnology and Merck have entered into an exclusive worldwide licensing agreement for use of PDS Biotechnology’s novel Versamune™ nanotechnology platform in two of Merck’s investigational antigen-specific cancer immunotherapies currently in pre-clinical development. Merck obtains the rights to utilize the technology with two investigational antigen-specific cancer immunotherapies which are in pre-clinical development.
Financial terms:
- Under the terms of the licensing agreement, PDS Biotechnology will receive an undisclosed upfront payment in cash, as well as development milestone payments, and commercial and sales milestone payments. PDS Biotechnology will also receive royalties on sales of the products incorporating the technology.
Latest news:
Is general: Yes
